See more : Hindprakash Industries Limited (HPIL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Incyte Corporation (INCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Incyte Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Bright Future Technology Holdings Limited (1351.HK) Income Statement Analysis – Financial Results
- SPT Energy Group Inc. (1251.HK) Income Statement Analysis – Financial Results
- Astronics Corporation (ATRO) Income Statement Analysis – Financial Results
- Zhejiang Xiantong Rubber&Plastic Co.,Ltd (603239.SS) Income Statement Analysis – Financial Results
- Australian Vanadium Limited (AVL.AX) Income Statement Analysis – Financial Results
Incyte Corporation (INCY)
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.70B | 3.39B | 2.99B | 2.67B | 2.16B | 1.88B | 1.54B | 1.11B | 753.75M | 511.50M | 354.95M | 297.06M | 94.46M | 169.88M | 9.27M | 3.92M | 34.44M | 27.64M | 7.85M | 14.15M | 47.09M | 101.61M | 219.26M | 194.17M | 157.00M | 134.80M | 88.40M | 41.80M | 12.20M | 200.00K | 300.00K |
| Cost of Revenue | 255.00M | 207.00M | 150.99M | 131.33M | 114.25M | 94.12M | 79.48M | 58.19M | 26.97M | 3.00M | 630.00K | 157.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -34.84M | -24.70M | -17.80M | -10.40M | -6.50M | -2.60M | -900.00K | 3.60M |
| Gross Profit | 3.44B | 3.19B | 2.84B | 2.54B | 2.04B | 1.79B | 1.46B | 1.05B | 726.78M | 508.49M | 354.32M | 296.90M | 94.46M | 169.88M | 9.27M | 3.92M | 34.44M | 27.64M | 7.85M | 14.15M | 47.09M | 101.61M | 219.26M | 229.01M | 181.70M | 152.60M | 98.80M | 48.30M | 14.80M | 1.10M | -3.30M |
| Gross Profit Ratio | 93.10% | 93.90% | 94.94% | 95.08% | 94.71% | 95.00% | 94.83% | 94.74% | 96.42% | 99.41% | 99.82% | 99.95% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 117.94% | 115.73% | 113.20% | 111.76% | 115.55% | 121.31% | 550.00% | -1,100.00% |
| Research & Development | 1.63B | 1.59B | 1.46B | 2.22B | 1.15B | 1.20B | 1.33B | 581.86M | 479.51M | 347.52M | 260.44M | 210.39M | 178.71M | 123.88M | 119.44M | 146.36M | 104.89M | 87.60M | 95.62M | 88.27M | 116.25M | 152.37M | 213.34M | 192.56M | 146.80M | 97.20M | 68.90M | 40.90M | 19.30M | 0.00 | 0.00 |
| General & Administrative | 1.16B | 1.00B | 739.60M | 516.90M | 453.41M | 434.41M | 366.41M | 303.25M | 196.61M | 165.77M | 109.98M | 85.36M | 58.22M | 32.33M | 27.58M | 17.07M | 15.24M | 16.91M | 13.01M | 74.73M | 30.33M | 47.15M | 70.63M | 64.20M | 37.20M | 25.40M | 12.10M | 6.80M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 40.00K | -40.00K | 22.00K | 15.30M | 10.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.16B | 1.00B | 739.56M | 516.92M | 468.71M | 434.41M | 366.41M | 303.25M | 196.61M | 165.77M | 109.98M | 85.36M | 58.22M | 32.33M | 27.58M | 17.07M | 15.24M | 16.91M | 13.01M | 74.73M | 30.33M | 47.15M | 70.63M | 64.20M | 37.20M | 25.40M | 12.10M | 6.80M | 3.90M | 12.30M | 1.20M |
| Other Expenses | 31.23M | 7.97M | 37.02M | 42.80M | 52.18M | 31.76M | 7.70M | 17.42M | 0.00 | 0.00 | 0.00 | 0.00 | 712.00K | -379.00K | 2.01M | -227.00K | -407.00K | 0.00 | 0.00 | 0.00 | 15.87M | 0.00 | 0.00 | 34.84M | 24.70M | 17.80M | 10.40M | 6.50M | 6.50M | 13.20M | 1.60M |
| Operating Expenses | 2.82B | 2.60B | 2.23B | 2.78B | 1.62B | 1.63B | 1.69B | 885.11M | 676.13M | 513.30M | 370.42M | 295.75M | 237.64M | 155.83M | 149.03M | 163.21M | 119.72M | 104.51M | 108.63M | 163.00M | 162.44M | 199.52M | 283.96M | 291.60M | 208.70M | 140.40M | 91.40M | 54.20M | 25.80M | 13.20M | 1.60M |
| Cost & Expenses | 3.08B | 2.80B | 2.39B | 2.91B | 1.74B | 1.73B | 1.77B | 943.30M | 703.10M | 516.30M | 371.05M | 295.91M | 237.64M | 155.83M | 149.03M | 163.21M | 119.72M | 104.51M | 108.63M | 163.00M | 162.44M | 199.52M | 283.96M | 256.76M | 184.00M | 122.60M | 81.00M | 47.70M | 23.20M | 12.30M | 5.20M |
| Interest Income | 172.35M | 39.93M | 10.65M | 2.17M | 1.86M | 0.00 | 17.50M | 4.41M | 7.09M | 3.35M | 1.32M | 764.00K | 462.00K | 1.42M | 50.00K | 5.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.55M | 2.67M | 1.91M | 2.17M | 1.86M | 1.54M | 6.90M | 38.75M | 45.60M | 46.83M | 38.65M | 46.06M | 43.82M | 43.32M | 32.13M | 5.31M | 22.43M | 12.53M | 12.53M | 3.56M | 0.00 | 9.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 82.66M | 67.86M | 57.84M | 51.81M | 54.53M | 54.97M | 52.18M | 58.43M | 44.88M | 41.41M | 29.21M | 29.98M | 26.99M | 24.49M | 16.69M | 13.07M | 12.96M | 7.41M | 8.19M | 13.91M | 17.69M | 23.21M | 47.67M | 34.84M | 24.70M | 17.80M | 10.40M | 6.50M | 2.60M | 900.00K | 400.00K |
| EBITDA | 919.43M | 599.64M | 630.20M | -178.24M | 475.66M | 209.84M | -253.21M | 204.57M | 98.04M | 39.96M | -14.99M | 31.89M | -115.73M | 35.96M | -123.08M | -146.22M | -72.32M | -76.86M | -92.59M | -132.06M | -149.30M | -110.52M | -17.03M | -27.75M | -2.30M | 30.00M | 14.00M | -2.40M | -8.10M | -11.20M | -4.50M |
| EBITDA Ratio | 24.88% | 18.60% | 20.47% | -8.14% | 21.95% | 9.95% | -14.23% | 15.09% | 7.66% | -0.28% | -4.16% | 0.64% | -151.59% | 10.62% | -1,076.54% | -3,736.80% | -211.16% | -268.72% | -1,185.22% | -949.10% | -103.41% | -36.62% | 54.07% | -13.63% | 2.10% | 26.93% | 15.84% | 3.11% | -78.69% | -5,950.00% | -1,566.67% |
| Operating Income | 620.53M | 579.44M | 585.78M | -240.29M | 402.01M | 129.22M | -243.73M | 145.00M | 50.65M | -4.80M | -16.10M | 1.15M | -143.18M | 14.05M | -139.77M | -159.29M | -85.28M | -76.86M | -100.78M | -148.85M | -149.30M | -97.91M | -64.70M | -62.59M | -27.00M | 12.20M | 7.40M | -5.90M | -11.00M | -12.10M | -4.90M |
| Operating Income Ratio | 16.79% | 17.07% | 19.62% | -9.01% | 18.62% | 6.87% | -15.87% | 13.11% | 6.72% | -0.94% | -4.54% | 0.39% | -151.59% | 8.27% | -1,508.56% | -4,064.53% | -247.62% | -278.06% | -1,284.53% | -1,052.26% | -317.03% | -96.35% | -29.51% | -32.24% | -17.20% | 9.05% | 8.37% | -14.11% | -90.16% | -6,050.00% | -1,633.33% |
| Total Other Income/Expenses | 213.69M | -50.32M | -15.33M | 31.46M | 84.79M | -13.88M | -68.90M | -37.59M | -43.10M | -43.74M | -66.75M | -45.29M | -43.36M | -45.90M | -72.10M | -19.63M | -1.60M | 2.70M | -3.13M | -14.36M | -16.69M | 2.70M | -122.27M | 29.92M | -600.00K | -6.30M | 0.00 | 2.30M | 1.10M | 700.00K | 200.00K |
| Income Before Tax | 834.22M | 529.12M | 570.44M | -232.22M | 486.79M | 115.35M | -312.29M | 107.40M | 7.56M | -48.55M | -82.85M | -44.15M | -186.54M | -31.85M | -211.87M | -178.92M | -86.88M | -74.17M | -103.91M | -163.21M | -165.99M | -135.77M | -186.97M | -32.67M | -27.60M | 5.90M | 10.90M | -6.60M | -9.80M | -11.40M | -4.70M |
| Income Before Tax Ratio | 22.57% | 15.59% | 19.10% | -8.71% | 22.55% | 6.13% | -20.33% | 9.71% | 1.00% | -9.49% | -23.34% | -14.86% | -197.49% | -18.75% | -2,286.78% | -4,565.45% | -252.27% | -268.30% | -1,324.36% | -1,153.76% | -352.47% | -133.61% | -85.27% | -16.82% | -17.58% | 4.38% | 12.33% | -15.79% | -80.33% | -5,700.00% | -1,566.67% |
| Income Tax Expense | 236.62M | 188.46M | -378.14M | 63.48M | 39.89M | 5.85M | 852.00K | 3.18M | 1.03M | -66.00K | 299.00K | 174.00K | -26.99M | 21.41M | 55.41M | 19.63M | 1.60M | -552.00K | -552.00K | 453.00K | 477.00K | 1.12M | 930.00K | 205.00K | -800.00K | 2.40M | 500.00K | 900.00K | -900.00K | -600.00K | 0.00 |
| Net Income | 597.60M | 340.66M | 948.58M | -295.70M | 446.91M | 109.49M | -313.14M | 104.22M | 6.53M | -48.48M | -83.15M | -44.32M | -186.54M | -31.85M | -211.87M | -178.92M | -86.88M | -74.17M | -103.04M | -164.82M | -166.46M | -136.89M | -183.24M | -29.74M | -26.80M | 3.50M | 10.40M | -6.80M | -10.10M | -11.50M | -4.90M |
| Net Income Ratio | 16.17% | 10.04% | 31.76% | -11.09% | 20.70% | 5.82% | -20.38% | 9.43% | 0.87% | -9.48% | -23.43% | -14.92% | -197.49% | -18.75% | -2,286.78% | -4,565.45% | -252.27% | -268.30% | -1,313.32% | -1,165.11% | -353.48% | -134.71% | -83.57% | -15.31% | -17.07% | 2.60% | 11.76% | -16.27% | -82.79% | -5,750.00% | -1,633.33% |
| EPS | 2.67 | 1.53 | 4.30 | -1.36 | 2.08 | 0.52 | -1.53 | 0.55 | 0.04 | -0.29 | -0.56 | -0.34 | -1.49 | -0.26 | -2.06 | -1.99 | -1.03 | -0.89 | -1.24 | -2.21 | -2.33 | -2.03 | -2.77 | -0.47 | -0.48 | 0.07 | 0.14 | -0.17 | -0.31 | -0.41 | -0.19 |
| EPS Diluted | 2.65 | 1.52 | 4.27 | -1.36 | 2.05 | 0.51 | -1.53 | 0.54 | 0.03 | -0.29 | -0.56 | -0.34 | -1.49 | -0.26 | -2.06 | -1.99 | -1.03 | -0.89 | -1.24 | -2.21 | -2.33 | -2.03 | -2.77 | -0.47 | -0.48 | 0.06 | 0.13 | -0.17 | -0.31 | -0.41 | -0.19 |
| Weighted Avg Shares Out | 223.63M | 222.00M | 220.43M | 218.07M | 214.91M | 212.38M | 204.58M | 187.87M | 179.60M | 167.18M | 148.40M | 129.75M | 125.36M | 121.63M | 102.94M | 89.79M | 84.19M | 83.80M | 83.32M | 74.56M | 71.37M | 67.40M | 66.19M | 63.21M | 56.28M | 53.84M | 49.29M | 40.00M | 33.00M | 28.05M | 25.58M |
| Weighted Avg Shares Out (Dil) | 225.93M | 223.96M | 222.07M | 218.07M | 217.66M | 215.64M | 204.58M | 194.13M | 187.30M | 167.95M | 148.40M | 129.75M | 125.36M | 121.63M | 102.94M | 89.79M | 84.19M | 83.80M | 83.32M | 74.56M | 71.37M | 67.40M | 66.19M | 63.21M | 56.28M | 57.80M | 53.08M | 40.00M | 33.00M | 28.05M | 25.58M |
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
GMAB or INCY: Which Is the Better Value Stock Right Now?
Incyte to Report Third Quarter Financial Results
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Incyte Announces Promising New Data on Oncology Candidate at ESMO
Source: https://incomestatements.info
Category: Stock Reports